- Home
- SGHT
SGHT
Sight Sciences Inc.
as 07-05-2024 4:00pm EST
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 277.1M | IPO Year: | 2021 |
| Target Price: | $5.10 | AVG Volume (30 days): | 200.1K |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.04 - $9.31 | Next Earning Date: | 08-01-2024 |
| Revenue: | $81,496,000 | Revenue Growth: | 8.27% |
| Revenue Growth (this year): | 5.49% | Revenue Growth (next year): | 12.42% |
Stock Insider Trading Activity of Sight Sciences Inc. (SGHT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Park Sam Boong | SGHT | Chief Operating Officer | Jul 2 '24 | Sell | $6.21 | 3,525 | $21,897.30 | 258,229 | SEC Form 4 |
| HAYDEN JEREMY B. | SGHT | Chief Legal Officer | Jul 2 '24 | Sell | $6.21 | 5,055 | $31,401.66 | 163,565 | SEC Form 4 |
| Badawi David | SGHT | Chief Technology Officer | Jul 1 '24 | Sell | $6.42 | 3,128 | $20,072.38 | 1,759,648 | SEC Form 4 |
| Bauerlein Alison | SGHT | Chief Financial Officer | May 17 '24 | Sell | $5.42 | 13,066 | $70,869.98 | 413,182 | SEC Form 4 |
| Bauerlein Alison | SGHT | Chief Financial Officer | Apr 3 '24 | Sell | $5.08 | 10,123 | $51,414.72 | 426,248 | SEC Form 4 |
| Badawi David | SGHT | Chief Technology Officer | Apr 3 '24 | Sell | $5.08 | 3,128 | $15,887.11 | 1,762,776 | SEC Form 4 |
| HAYDEN JEREMY B. | SGHT | Chief Legal Officer | Apr 3 '24 | Sell | $5.08 | 4,893 | $24,851.55 | 168,620 | SEC Form 4 |
| Badawi Paul | SGHT | President and CEO | Apr 3 '24 | Sell | $5.08 | 12,571 | $63,848.11 | 5,750,729 | SEC Form 4 |
| Park Sam Boong | SGHT | Chief Operating Officer | Apr 3 '24 | Sell | $5.08 | 3,414 | $17,339.71 | 261,754 | SEC Form 4 |
| Park Sam Boong | SGHT | Chief Operating Officer | Jan 17 '24 | Sell | $5.16 | 5,443 | $28,107.65 | 100,735 | SEC Form 4 |
| Badawi Paul | SGHT | President and CEO | Jan 17 '24 | Sell | $5.16 | 15,917 | $82,195.39 | 5,319,539 | SEC Form 4 |
| Badawi David | SGHT | Chief Technology Officer | Jan 17 '24 | Sell | $5.16 | 3,414 | $17,629.90 | 1,642,157 | SEC Form 4 |
| HAYDEN JEREMY B. | SGHT | Chief Legal Officer | Jan 17 '24 | Sell | $5.16 | 4,538 | $23,434.23 | 10,318 | SEC Form 4 |
| D1 Capital Partners L.P. | SGHT | 10% Owner | Dec 27 '23 | Sell | $5.86 | 2,852,036 | $16,712,930.96 | 3,000,000 | SEC Form 4 |
| Encrantz Staffan | SGHT | Director10% Owner | Nov 29 '23 | Buy | $3.50 | 3,223 | $11,280.50 | 871,373 | SEC Form 4 |
| Encrantz Staffan | SGHT | Director10% Owner | Nov 29 '23 | Buy | $3.46 | 140,777 | $486,637.93 | 1,012,150 | SEC Form 4 |
| Encrantz Staffan | SGHT | Director10% Owner | Nov 24 '23 | Buy | $3.09 | 21,855 | $67,427.05 | 368,150 | SEC Form 4 |
| Encrantz Staffan | SGHT | Director10% Owner | Nov 24 '23 | Buy | $3.31 | 246,331 | $815,946.80 | 614,481 | SEC Form 4 |
| Encrantz Staffan | SGHT | Director10% Owner | Nov 20 '23 | Buy | $2.25 | 79,234 | $178,189.34 | 236,733 | SEC Form 4 |
| Encrantz Staffan | SGHT | Director10% Owner | Nov 20 '23 | Buy | $2.48 | 68,477 | $169,535.36 | 305,210 | SEC Form 4 |
| Encrantz Staffan | SGHT | Director10% Owner | Nov 20 '23 | Buy | $2.50 | 41,085 | $102,708.39 | 346,295 | SEC Form 4 |
| Encrantz Staffan | SGHT | Director10% Owner | Nov 14 '23 | Buy | $2.00 | 3,462 | $6,913.61 | 30,496 | SEC Form 4 |
Latest Sight Sciences Inc. News
SGHT Breaking Stock News: Dive into SGHT Ticker-Specific Updates for Smart Investing
Simply Wall St.
23 days ago
One Sight Sciences Insider Raised Stake By 34% In Previous Year
GlobeNewswire
a month ago
Sight Sciences Announces the Release of its First Sustainability Report
MT Newswires
a month ago
Sight Sciences Trial Results Show Improved Dry Eye Disease Signs, Symptoms for TearCare Patients Crossed Over From Restasis
GlobeNewswire
a month ago
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
GlobeNewswire
a month ago
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma
GlobeNewswire
2 months ago
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference
Insider Monkey
2 months ago
Sight Sciences, Inc. (NASDAQ:SGHT) Q1 2024 Earnings Call Transcript
Simply Wall St.
2 months ago
Sight Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Share on Social Networks:
Disclaimer
The information presented on this page, "SGHT Sight Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.